|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
American Cancer Society. Cancer Facts
& Figures 2015 (Atlanta). American Cancer Society. 2015.
|
|
4
|
Kris MG, Johnson BE, Kwiatkowski DJ,
Iafrate AJ, Wistuba II, Aronson SL, Engelman JA, Shyr Y, Khuri FR,
Rudin CM, et al: Identification of driver mutations in tumor
specimens from 1,000 patients with lung adenocarcinoma: The NCI's
lung cancer mutation consortium (LCMC). J Clin Oncol. 29 (18
Suppl):787S2011. View Article : Google Scholar
|
|
5
|
Rosell R, Carcereny E, Gervais R,
Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R,
Pallares C, Sanchez JM, et al: Erlotinib versus standard
chemotherapy as first-line treatment for European patients with
advanced EGFR mutationpositive non-small-cell lung cancer (EURTAC):
A multicentre, open-label, randomised phase 3 trial. Lancet Oncol.
13:239–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Gentzler RD, Yentz SE and Patel JD:
Bevacizumab in advanced NSCLC: Chemotherapy partners and duration
of use. Curr Treat Options Oncol. 14:595–609. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mattern J, Koomägi R and Volm M:
Association of vascular endothelial growth factor expression with
intratumoral microvessel density and tumour cell proliferation in
human epidermoid lung carcinoma. Br J Cancer. 73:931–934. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brown LF, Berse B, Jackman RW, Tognazzi K,
Manseau EJ, Senger DR and Dvorak HF: Expression of vascular
permeability factor (vascular endothelial growth factor) and its
receptors in adenocarcinomas of the gastrointestinal tract. Cancer
Res. 53:4727–4735. 1993.PubMed/NCBI
|
|
9
|
Brown LF, Berse B, Jackman RW, Tognazzi K,
Guidi AJ, Dvorak HF, Senger DR, Connolly JL and Schnitt SJ:
Expression of vascular permeability factor (vascular endothelial
growth factor) and its receptors in breast cancer. Hum Pathol.
26:86–91. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Seto T, Higashiyama M, Funai H, Imamura F,
Uematsu K, Seki N, Eguchi K, Yamanaka T and Ichinose Y: Prognostic
value of expression of vascular endothelial growth factor and its
flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung
Cancer. 53:91–96. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ferrara N, Gerber HP and LeCouter J: The
biology of VEGF and its receptors. Nat Med. 9:669–676. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Kim KJ, Li B, Winer J, Armanini M, Gillett
N, Phillips HS and Ferrara N: Inhibition of vascular endothelial
growth factorinduced angiogenesis suppresses tumour growth in vivo.
Nature. 36:841–844. 1993. View Article : Google Scholar
|
|
13
|
Kabbinavar FF, Wong JT, Ayala RE, Wintroub
AB, Kim KJ and Ferrara N: The effect of antibody to vascular
endothelial growth factor and cisplatin on the growth of lung
tumors in nude mice. Proc Am Assoc Cancer Res. 36:4881995.
|
|
14
|
Armanini M, Gillett N, Phillips HS and
Ferrara N: Importance of VEGF for breast cancer angiogenesis in
vivo: Implications from intravital microscopy of combination
treatments with an anti-VEGF neutralizing monoclonal antibody and
doxorubicin. Anticancer Res. 19:4203–4214. 1999.PubMed/NCBI
|
|
15
|
Qu CY, Zheng Y, Zhou M, Zhang Y, Shen F,
Cao J and Xu LM: Value of bevacizumab in treatment of colorectal
cancer: A meta-analysis. World J Gastroenterol. 21:5072–5080. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yoshida H, Yabuno A and Fujiwara K:
Critical appraisal of bevacizumab in the treatment of ovarian
cancer. Drug Des Devel Ther. 9:2351–2358. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Miller K, Armanini M, Gillett N, Phillips
HS and Ferrara N: Paclitaxel plus bevacizumab versus paclitaxel
alone for metastatic breast cancer. N Engl J Med. 357:2666–2676.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bear HD, Tang G, Rastogi P, Geyer CE Jr,
Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher
L, et al: Neoadjuvant plus adjuvant bevacizumab in early breast
cancer [NSABP B-40 (NRG Oncology)]: Secondary outcomes of a phase
3, randomised controlled trial. Lancet Oncol. 16:1037–1048. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Turnbull JD, Cobert J, Jaffe T, Harrison
MR, George DJ and Armstrong AJ: Activity of single-agent
bevacizumab in patients with metastatic renal cell carcinoma
previously treated with vascular endothelial growth factor tyrosine
kinase inhibitors. Clin Genitourin Cancer. 11:45–50. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Escudier B, Pluzanska A, Koralewski P,
Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar
B, Bajetta E, et al: Bevacizumab plus interferon alfa-2a for
treatment of metastatic renal cell carcinoma: A randomised,
double-blind phase III trial. Lancet. 370:2103–3111. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Johnson DH, Fehrenbacher L, Novotny WF,
Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF III,
Gaudreault J, Damico LA, et al: Randomized phase II trial comparing
bevacizumab plus carboplatin and paclitaxel with carboplatin and
paclitaxel alone in previously untreated locally advanced or
metastatic non-small-cell lung cancer. J Clin Oncol. 22:2184–2191.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Novotny WF, Holmgren E, Griffing S, et al:
Identification of squamous cell histology and central, cavitary
tumors as possible risk factors for pulmonary hemorrhage (PH) in
patients with advanced NSCLC receiving bevacizumab (BV). Proc Am
Soc Clin Oncol. 20:A13182001.
|
|
24
|
Sandler A, Gray R, Perry MC, Brahmer J,
Schiller JH, Dowlati A, Lilenbaum R and Johnson DH:
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell
lung cancer. N Engl J Med. 355:2542–2550. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Reck M, von Pawel J, Zatloukal P, Ramlau
R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N and
Manegold C: Phase III trial of cisplatin plus gemcitabine with
either placebo or bevacizumab as first-line therapy for nonsquamous
non-small-cell lung cancer: AVAil. J Clin Oncol. 27:1227–1234.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Reck M, von Pawel J, Zatloukal P, Ramlau
R, Gorbounova V, Hirsh V, Leighl N, Mezger J, Archer V, Moore N, et
al: Overall survival with cisplatin-gemcitabine and bevacizumab or
placebo as first-line therapy for nonsquamous non-small-cell lung
cancer: Results from a randomised phase III trial (AVAiL). Ann
Oncol. 21:1804–1809. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Saad ED and Katz A: Progression-free
survival and time to progression as primary end points in advanced
breast cancer: Often used, sometimes loosely defined. Ann Oncol.
20:460–464. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lynch TJ Jr, Spigel DR, Brahmer J,
Fischbach N, Garst J, Jahanzeb M, Kumar P, Vidaver RM, Wozniak AJ,
Fish S, et al: Safety and effectiveness of bevacizumab-containing
treatment for non-small-cell lung cancer: Final results of the
ARIES observational cohort study. J Thorac Oncol. 9:1332–9. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Crinò L, Dansin E, Garrido P, Griesinger
F, Laskin J, Pavlakis N, Stroiakovski D, Thatcher N, Tsai CM, Wu YL
and Zhou C: Safety and efficacy of first-line bevacizumab-based
therapy in advanced non-squamous non-small-cell lung cancer (SAiL,
MO19390): A phase 4 study. Lancet Oncol. 11:733–740. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Quaresma M, Coleman MP and Rachet B:
40-year trends in an index of survival for all cancers combined and
survival adjusted for age and sex for each cancer in England and
Wales, 1971–2011: A population-based study. Lancet. 385:1206–1218.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lauro S, Onesti CE, Righini R and
Marchetti P: The use of bevacizumab in non-small cell lung cancer:
An update. Anticancer Res. 34:1537–1545. 2014.PubMed/NCBI
|
|
32
|
Simmons CP, Koinis F, Fallon MT, Fearon
KC, Bowden J, Solheim TS, Gronberg BH, McMillan DC, Gioulbasanis I
and Laird BJ: Prognosis in advanced lung cancer-A prospective study
examining key clinicopathological factors. Lung Cancer. 88:304–309.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
de Kock I, Mirhosseini M, Lau F, Thai V,
Downing M, Quan H, Lesperance M and Yang J: Conversion of karnofsky
performance status (KPS) and eastern cooperative oncology group
performance status (ECOG) to palliative performance scale (PPS) and
the interchangeability of PPS and KPS in prognostic tools. J
Palliat Care. 29:163–169. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sengupta A, Banerjee SN, Biswas NM, Jash
D, Saha K, Maji A, Bandyopadhyaya A and Agarwal S: The incidence of
hyponatraemia and its effect on the ECOG performance status among
lung cancer patients. J Clin Diagn Res. 7:1678–1682.
2013.PubMed/NCBI
|
|
35
|
Young J, Badgery-Parker T, Dobbins T,
Jorgensen M, Gibbs P, Faragher I, Jones I and Currow D: Comparison
of ECOG/WHO performance status and ASA score as a measure of
functional status. J Pain Symptom Manage. 49:258–264. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Griesinger F, B.A, Eberhardt W, Garrido P,
Isla D, Ko Y, Kohlhaufl M, Schneider C, Thatcher T and Palakis N:
Safety of first line bevacizumab-based therapy in the SAiL
(MO19390) trial: Central trumor location and hypertension in
patients with advanced non-small cell lung cancer. Ann Oncol. 21
Suppl 8:(viii): 1442010.
|
|
37
|
Kumar P, Fishbach NA, Brahmer JR, Spigel
DR, Beatty S, Teng S, Flick ED, Sing A and Lynch TJ: Baseline
radiographic characteristics and severe pulmonary hemorrhage in
bevacizumab-treated non-small cell lung cancer patients: Results
from ARIES, an observational cohort study. J Clin Oncol. 28
Suppl:(15s): A76192010. View Article : Google Scholar
|
|
38
|
Sandler AB, Schiller JH, Gray R, Dimery I,
Brahmer J, Samant M, Wang LI and Johnson DH: Retrospective
evaluation of the clinical and radiographic risk factors associated
with severe pulmonary hemorrhage in first-line advanced,
unresectable non-small-cell lung cancer treated with Carboplatin
and Paclitaxel plus bevacizumab. J Clin Oncol. 27:1405–1412. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chemotherapy in non-small cell lung
cancer: A meta-analysis using updated data on individual patients
from 52 randomised clinical trials. Non-small Cell Lung Cancer
Collaborative Group. BMJ. 311:899–909. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Marino P, Pampallona S, Preatoni A,
Cantoni A and Invernizzi F: Chemotherapy vs supportive care in
advanced non-small-cell lung cancer. Results of a meta-analysis of
the literature. Chest. 106:861–865. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ezer N, Smith CB, Galsky MD, Mhango G, Gu
F, Gomez J, Strauss GM and Wisnivesky J: Cisplatin vs.
carboplatin-based chemoradiotherapy in patients >65 years of age
with stage III non-small cell lung cancer. Radiother Oncol.
112:272–278. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Santana-Davila R, Szabo A, Arce-Lara C,
Williams CD, Kelley MJ and Whittle J: Cisplatin versus
carboplatin-based regimens for the treatment of patients with
metastatic lung cancer. An analysis of Veterans Health
Administration data. J Thorac Oncol. 9:702–709. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Smit E, Moro-Sibilot D, Carpeño Jde C,
Lesniewski-Kmak K, Aerts J, Villatoro R, Kraaij K, Nacerddine K,
Dyachkova Y, Smith KT, et al: Cisplatin and carboplatin-based
chemotherapy in the first-line treatment of non-small cell lung
cancer: Analysis from the European FRAME study. Lung Cancer.
92:35–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
de Castria TB, da Silva EM, Gois AF and
Riera R: Cisplatin versus carboplatin in combination with
third-generation drugs for advanced non-small cell lung cancer.
Cochrane Database Syst Rev. 8:CD0092562013.
|
|
45
|
Sun X and Zheng Y: Cisplatin or
Carboplatin for advanced non-small-cell lung cancer? J Thorac
Oncol. 9:e702014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tiseo M, Ardizzoni A and Boni L:
First-line chemotherapy treatment of advanced non-small-cell lung
cancer: Does cisplatin versus carboplatin make a difference? J
Thorac Oncol. 9:e822014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dranitsaris G, Beegle N, Ravelo A,
Kalberer T, Yu E and Thomas S: Evaluating the impact of bevacizumab
maintenance therapy on overall survival in advanced non-small-cell
lung cancer. Clin Lung Cancer. 14:120–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gridelli C, Bennouna J, de Castro J,
Dingemans AM, Griesinger F, Grossi F, Rossi A, Thatcher N, Wong EK
and Langer C: Randomized phase IIIb trial evaluating the
continuation of bevacizumab beyond disease progression in patients
with advanced non-squamous non-small-cell lung cancer after
first-line treatment with bevacizumab plus platinum-based
chemotherapy: Treatment rationale and protocol dynamics of the
AvaALL (MO22097) trial. Clin Lung Cancer. 12:407–411. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Patel JD, Socinski MA, Garon EB, Reynolds
CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA,
et al: PointBreak: A randomized phase III study of pemetrexed plus
carboplatin and bevacizumab followed by maintenance pemetrexed and
bevacizumab versus paclitaxel plus carboplatin and bevacizumab
followed by maintenance bevacizumab in patients with stage IIIB or
IV nonsquamous non-small-cell lung cancer. J Clin Oncol.
31:4349–4357. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Barlesi F, Scherpereel A, Gorbunova V,
Gervais R, Vikström A, Chouaid C, Chella A, Kim JH, Ahn MJ, Reck M,
et al: Maintenance bevacizumab-pemetrexed after first-line
cisplatin-pemetrexed-bevacizumab for advanced nonsquamous
nonsmall-cell lung cancer: Updated survival analysis of the AVAPERL
(MO22089) randomized phase III trial. Ann Oncol. 25:1044–1052.
2014. View Article : Google Scholar : PubMed/NCBI
|
